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Abstract
Sports medicine physicians often treat athletes in pain with non-steroidal anti-inflammatory drugs (NSAIDs). However, there is a lack of high-
quality evidence to guide NSAID use. Their adverse effects have clinical relevance, and their possible negative consequences on the long-term
healing process are slowly becoming more obvious. This article provides some practical management guidelines for the use of NSAIDs, developed
to help sports medicine physicians deal with frequent sports-related injuries. We do not recommend their use for muscle injuries, bone fractures
(also stress fractures) or chronic tendinopathy. In all cases, if chosen, NSAID treatments should always be kept as short as possible and should take
into account the specific type of injury, the level of dysfunction and pain.
# 2010 Elsevier Masson SAS. All rights reserved.
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Re´sume´
L’e´pisode douloureux en me´decine du sport est fre´quemment traite´ par des anti-inflammatoires non ste´roı¨diens. Pourtant, a` l’heure actuelle, une
controverse se fait jour quant a` leur efficacite´ et leurs effets secondaires ne sont pas anodins. L’inhibition de la re´ponse inflammatoire pre´coce peut
alte´rer la cicatrisation naturelle d’une le´sion et avoir un impact ne´gatif sur le processus de re´paration ulte´rieur. Dans le cas de le´sions ligamentaires
fraıˆches, l’administration d’anti-inflammatoires non ste´roı¨diens paraıˆt eˆtre une option utile, a` condition de respecter une cure de courte dure´e. Lors
de tendinopathie par surcharge, il n’y a pas a` proprement parler de phe´nome`ne inflammatoire ; de fait, les anti-inflammatoires non ste´roı¨diens ne
sont pas recommande´s. Il convient aussi de les e´viter apre`s une fracture en raison de leurs effets de´le´te`res sur la formation osseuse. Enfin, les e´tudes
ne de´montrent pas d’inte´reˆt notable a` leur utilisation lors de le´sions musculaires aigue¨s. Une re´flexion s’impose donc pour savoir s’il est justifie´ de
masquer les symptoˆmes douloureux d’un athle`te afin de lui permettre une interruption la plus courte possible de sa pratique sportive, au de´triment
peut-eˆtre de sa gue´rison.
# 2010 Elsevier Masson SAS. Tous droits re´serve´s.
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1.1. Introduction
The supposed best method for the immediate treatment of
most sports injuries is well known: rest, ice, compression and
elevation (RICE protocol). However, although it seems to make* Corresponding author.
E-mail address: Jean-luc.ziltener@hcuge.ch (J.L. Ziltener).
1877-0657/$ – see front matter # 2010 Elsevier Masson SAS. All rights reserved
doi:10.1016/j.rehab.2010.03.001sense to continue recommending the use of this protocol, no
study has really proved its advantages [15].
In order to reduce traumatic or post-traumatic pain, the
current practice is to prescribe analgesics or non-steroidal anti-
inflammatory drugs (NSAIDs). However, NSAIDs are not
without side effects and, despite these side effects, some
NSAIDs are sold as over-the-counter drugs, or at least are
accessible without strict medical control.
For various reasons, athletes regularly take NSAIDs in order
to continue their athletic activities, despite acute traumatic
injuries or overload injuries. They also want to accelerate their.
Table 1
Non-steroidal anti-inflammatory drug classification by plasma half-life.
Short Half-life < 6 h Long half-life > 6 h
Aspirin 25–330 Diflunisal 8–12
Diclofenac 1–2 Naproxen 12–15
Ibuprofen 1–2.5 Salsalate 3.5–16
Ketoprofen 1.5–4 Sulindac 16–18
Fenoprofen 2–3 Piroxicam 24–38
Mefanamic acid 2–4 Nabumetone 24
Meclofenamate 3–4 Oxaprozin 25




Fig. 1. The arachidonic acid cascade.
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NSAIDs as a preventive measure. For example, during the 2000
Olympic Games in Sydney, Canadian athletes used NSAIDs
more than any other medication [20]. Similarly, a survey of
American football players showed that one out of seven high
school athletes took NSAIDs daily and the 29% of college
athletes took them as a preventive measure on the day of a game
[52]. Warner et al. found a similar occurrence in their study of
athletes: independent of their analgesic effect, the athletes
mentioned a potential performance improvement to justify
taking these medications [54].
For a sizeable number of practitioners, the medical
knowledge about the harmful consequences of regular use of
NSAIDs is limited to gastrointestinal (GI) disorders and renal
function. However, recent medical literature has shown that the
harmful effects of NSAIDs extend to cell metabolism and
growth of the primary tissues making up the musculoskeletal
system [44]. These recent developments raise an ‘‘ethical’’
question for clinical practice: should medical practitioners only
take into account the short-term analgesic effect of NSAIDs in
order to encourage immediate performance improvements, or
would it be better to stress the potential harmful long-term
consequences of their use?
This article doesn’t attempt an exhaustive analysis of the
literature on this subject. Rather, it provides an update destined
to help primary care physicians, general practitioners and sports
medicine specialists to better evaluate the risks and benefits
inherent to the occasional or regular use of NSAIDs for athletes,
whether the injury be to the ligament, tendon, bone or muscle.
To create this update, we used the traditional data sources,
Pubmed and Embase, from 1997 to 2008, with the following
keywords: non-steroidal anti-inflammatory, musculoskeletal
system, tendinopathy, bone fractures, ligament injuries and
muscle tears. We then each individually read all the article titles
and abstracts and selected those that dealt with the role of
NSAIDs in the motor system pathologies encountered
frequently in sports medicine. We chose a total of 55 articles
appearing in peer-reviewed journals, either literature reviews,
meta-analyses or random controlled studies. We didn’t attempt
to classify these articles with respect to their methodological
quality.
1.2. Non-steroidal anti-inflammatory drugs: general
information
1.2.1. Mechanisms of action
NSAIDs are most frequently administered orally; this
implies that, depending on their individual properties, NSAIDs
are absorbed by the digestive system, enter the bloodstream,
and are metabolized by the liver or the kidneys. NSAIDs can
also be administered topically or via intramuscular injection.
Table 1 provides a synthetic classification of the most common
NSAIDs, according to their plasma half-life.
As Fig. 1 shows, NSAIDs work by blocking cyclo-
oxygenase (Cox), thus inhibiting the synthesis of prostaglan-
dins from arachidonic acid, while one part of the arachidonic
acid cascade continues on the lipo-oxygenase pathway.Migration, aggregation and neutrophile and macrophage
functions are also inhibited. Two Cox iso-enzymes (which
probably have sub-classes) have been identified: a constitutive
form called Cox-1 and an inducible form called Cox-2. Cox-2 is
overexpressed locally in cases of inflammation, and the
prostaglandin synthesis that results from this overexpression
supports the lesional process. Traditional NSAIDs inhibit the
two iso-forms, which effectively reduces the inflammatory
response, but also reduces gastric protections and interferes
with renal function. Selective Cox-2 inhibitors have been
introduced to reduce these side effects, especially the gastric
ones.
In the light of these observations, it seems more and more
obvious that NSAIDs, because they inhibit the initial
inflammatory responses, can have a negative impact on the
repair process because they alter the natural healing process of
an injury.
1.2.2. Adverse effects
The adverse effects of all types of NSAIDs are related to the
GL, the cardiovascular systems, the kidneys and the liver. GL
side effects (i.e., dyspepsia, nausea, ulcers and bleeding) appear
primarily when NSAIDs are taken frequently. However, a much
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that of control subjects appears after only 1 month of regular
NSAID doses. The RR is 4.0 for such traditional NSAIDs as
diclofenac and naproxen, 3.0 for diclofenac taken with
misoprostol, 1.9 for rofecoxib and 1.0 for celecoxib [23,27].
As a preventive measure, it is thus recommended to limit the
length of administration, to take NSAIDs with meals and/or to
prescribe a proton pump inhibitor or to associate diclofenac and
misoprostol.
To reduce the adverse effects on GL system, selective
Cox-2 inhibitors were introduced in 1999. However, the
studies published after their introduction pointed out that
these substances disturb the prostacyclin–thromboxane
balance, which is essential for maintaining vascular home-
ostasis [41]. Disturbing this balance increases the risk of
thrombosis [17]. One of these selective Cox-2 inhibitors,
rofecoxib, was withdrawn from the market because of an
increased pro-thrombotic effect that was responsible for a
high number of vascular accidents. In Switzerland, another
one, valdecoxib, was also withdrawn from the market for
safety reasons. To our knowledge, only celecoxib was kept
on the market. If the RR of myocardial infarction is
evaluated, the RR of rofecoxib is 1.35 with a dose-dependant
effect (over 25 mg/day, the RR rises to 2.19), while celecoxib
has an RR of only 1.06. In addition, high RR values have also
been found for certain non-selective NSAIDs, such as
diclofenac and indomethacin, which have respective RR
values of 1.40 and 1.30 [26].
In addition, there is a risk of post-traumatic hemorrhage in
athletes involved in contact sports or ‘‘at-risk’’ sports [33,44]. A
less frequent side effect, renal failure, has been observed in
elderly subjects but also in dehydrated subjects. Since
dehydration happens frequently to athletes when playing
sports, this should be kept in mind.
1.3. Non-steroidal anti-inflammatory drugs: parenteral
forms
1.3.1. Topical applications
Large-scale clinical studies about topical anti-inflamma-
tories are rare, thus their conclusions are obviously incomplete
but interesting nonetheless. Topical NSAIDs appear to dispense
sub-cutaneous therapeutic doses through tissue penetration,
while reducing the adverse systemic effects by lowering the rate
of circulation of the substance in the bloodstream [42]. A meta-
analysis of diclofenac and ketoprofen applied topically for
acute or chronic benign sports-related soft-tissue injuries
compared to a placebo demonstrated a significant therapeutic
effectiveness of NSAIDs over the placebo. Including more than
10 000 subjects, this study was designed to evaluate the
tolerance of the treatment. Its effectiveness criterion was a pain
reduction of at least 50%. As stated above, NSAIDs were more
effective than the placebo for acute injuries (maximum length
of treatment: 1 week), with a relative benefit of 1.7 and a
number needed to treat (NNT) of 3.9. For chronic injuries
(maximum length of treatment: 2 weeks), the relative benefit
was 2.0 and the NNT was 3.1 [30].The recent development of NSAID patches allows a
controlled extended release of the active substance over 12
to 24 hours. Several recent controlled studies, testing diclofe-
nac patches [9] and ketoprofen patches [25] compared to a
cream and/or a placebo, confirmed the effectiveness of patches.
Again, the effectiveness criteria were the reduction of pain
(50%) and the tolerance to the treatment on a visual analogic
scale (VAS). However, using patches didn’t allow an
accelerated return to sport [4,34].
1.3.2. Intramuscular injections
The only published study—of questionable quality—
concerns ketorolac injections [7]. This study concludes that
there is no reduction of pain compared to ketorolac
administered orally. However, the adverse effects, such as an
increased global risk of hemorrhage and renal complications,
seem to be worse. This form of administration, nonetheless,
remains privileged in professional sports (i.e., ‘‘smart bombs’’)
for specific events [48].
1.4. Non-steroidal anti-inflammatory drugs and the
musculoskeletal system
1.4.1. Ligament injuries
Acute ligament injuries are repaired in three phases:
 an initial inflammatory phase, including the cleaning of
injured tissue;
 a proliferative phase, including the formation of collagen
fibers;
 a remodeling phase, which can last several months, when
controlled mechanical stress is applied to the injury.
The most available studies concern in-vitro or animal
models and examine the use of piroxicam, ibuprofen and
Cox-2 inhibitors for an injury to the knee’s medial collateral
ligament [40]. The results are contradictory: in the short
term, joint function is sometimes improved; in the medium
term, the ligament’s resistance to tension is increased,
decreased or remains the same; in the long term, potentially
deleterious effects on healing have been observed [6,8,31]. In
vitro, protein synthesis in human fibroblasts is also inhibited
by indomethacin [2].
For humans, the most studied injuries are acute sprains of the
ankle or knee. In one comparative study of a placebo versus
ibuprofen, the authors concluded that pain and swelling was
initially diminished, the joint amplitudes were improved, and
the load-bearing capacity was restored more rapidly. Positive
effects were observed up to the 7th day [13]. However, other
studies have shown that, after 6 months, groups treated with
another NSAIDs (piroxicam 20 mg/day for 7 days) showed
reduced joint amplitude, increased anterior laxity and a higher
recidivism rate (25%) [43].
NSAIDs thus appear to have a positive impact on the initial
evolution of an acute ligament injury, which argues for the
administration of NSAIDs for 3 to 7 days [27]. This could allow
a more rapid return to the athletic activity. However, in the long
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quality healing.
1.4.2. Tendon injuries
The role of NSAIDs in the treatment of overload
tendinopathy is uncertain and is subject to debate. In fact,
chronic tendinopathy doesn’t present inflammatory reaction
[16], other than in certain cases of bursitis or associated
synovitis. Moreover, frequently, persistent neovascularization
and neo-innervation could be partially responsible for the pain
[1].
A meta-analysis identified 37 random clinical studies, of
which 17 were placebo-controlled; this study highlighted that
only short-term pain (7 to 10 days) is reduced, particularly in
the shoulder. The analgesic effectiveness of NSAIDs is clearly
less for elbows, patellar tendons and Achilles tendons. This
meta-analysis didn’t mention any effect size calculated from
the diverse studies included in the statistical analysis [3].
In the long term, there is no evidence that NSAIDs are
effective for treating tendon injuries, whereas the risk of
adverse effects rises. Above all, the healing of a tendinopathy
does not seem to be modified by taking NSAIDs [24].
Moreover, the analgesic effect of NSAIDs permits athletes to
increase the stress on their tendons prematurely, and this stress
compromises the long-term cure [22].
Of the acute attacks, short-term treatment (up to 14 days)
with celecoxib [19] or naproxen [36] (compared to a placebo)
appears to be potentially indicated for true shoulder bursitis and
De Quervain’s tenosynovitis. The essential effectiveness
criteria are a maximal reduction in pain intensity at rest and
a good tolerance of the treatment.
1.4.3. Bone injuries
The Prostaglandin E (PGE) family plays an important role in
bone homeostasis. The members of this family stimulate both
bone resorption by increasing the number and the activity of
osteoclasts and bone formation by increasing osteoblasts
replication and differentiation [53]. It is thus understood that
any substance altering prostaglandin synthesis can have an
impact on the bone. For example, the inhibiting effects of
NSAIDs on bone formation can be used to prevent heterotopic
ossification following prosthetic surgery [11]. In the scientific
literature, numerous animal studies have demonstrated a delay
in bone consolidation when NSAIDs are taken, even the
selective Cox-2 [55].
Human studies have produced equivocal results for acute
bone trauma and after surgery. Most often, these studies are
retrospective or reflect particular situations, such as vertebral
fusion. The harmful effects of NSAIDs vary, according the
substance chosen as well as how long the substance was
administered. A delay in bone consolidation has been described
many times [12,18,37]. Because of these effects on bone
formation, it is recommended to avoid NSAIDs at least during
the first weeks after a fracture. Afterwards, even though certain
harmful effects are absent, their use is not really justified;
analgesics should be enough to take care of the pain. In cases of
stress fractures, NSAIDs should not be used for the samereasons. Thus, we recommend avoiding the administration of
NSAIDs, especially in the first week after a fracture and in cases
of stress fractures.
1.4.4. Muscle injuries
The gravity of muscle injuries depends on the degree to
which the muscle’s main constituents—the contractile tissue
and the support tissue—are affected. Immediately following a
rupture of the muscle fibers, myofiber necrosis and inflamma-
tion [14] result, with the dominant presence of neutrophiles and
macrophages. It is not yet known whether the role of these
neutrophiles and macrophages is positive or negative
[5,28,38,45–47]. In fact, for some authors, the neutrophiles
are responsible for liberating cytokines and free radicals, which
could make the initial injury worse. In the near future, selective
inhibitors of free radical production may be developed, which
would be an innovative pharmacological treatment [49]. In the
repair process that follows the injury, first, the macrophages
ingest the necrotic tissues in a process known as macrophage
phagocytosis. These macrophages are also a source of
cytokines and growth factors. Then, fibrous tissue is produced.
A remodeling phase is then undertaken in order to regenerate
new muscle fibers and to organize the fibrous tissue [50].
There are many animal models of muscular injuries treated
with NSAIDs. However, since transposing these results to
human beings may be risky and since the methodology of these
studies varies, it is difficult to draw unequivocal conclusions.
For this reason, we only report the results of studies conducted
with humans.
For Delayed Onset Muscle Soreness (DOMS), taking an
NSAID (ibuprofen; 1200 mg/day), versus taking an analgesic
(acetaminophen; 4 g/day) or a placebo, didn’t modify the
concentration of neutrophiles and macrophages in the muscles
for the three groups in this study [35]. Similarly, there was no
difference between the three groups in terms of the secondary
effectiveness criteria: the rate of creatine kinase (CK) or PGE2
and pain intensity. The same inhibition was observed for
prostaglandins and protein synthesis, whether the NSAID or the
analgesic was taken [51,52].
However, when an NSAID (indomethacin; 100 mg/day) was
administered from 4 days prior to the DOMS to 4 days after the
DOMS, a reduction of satellite cells induced by effort was
observed [21]; these cells are essential for muscle regeneration
and are dependant on the presence of prostaglandin. Thus,
taking NSAIDs regularly, which happens frequently in some
sports, may allow sufficient tissue concentrations to be reached
to potentially modify the local response.
This hypothesis was also supported in a study reporting that,
compared to a placebo, the prolonged administration of
diclofenac, beginning 15 days before an unusual eccentric
effort, allows the increase in CK to be limited and the period of
discomfort linked to sore muscles to be decreased, which are
the effectiveness criteria commonly used in studies about
muscles soreness [32].
In the more traditional context of an acute muscle trauma
(i.e., tears or strains), taking an NSAID (diclofenac; 150 mg/
day) or an analgesic (meclofenamate; 300 mg/day) or a placebo
Table 2
The conclusions of the authors about using NSAIDs in sports medicine.
Type of injury NSAID Impact Comments
Ligament: acute sprain Possibly and potentially
useful in the short-term
Reduces pain and swelling
Faster return to athletic activities
Long-term residual laxity (???)
Short-term use (< 5 days)
Tendon: true acute tenosynovitis Possibly and potentially useful Reduces acute inflammations
Helps recovery
Tendon: overuse tendinopathy Probably not useful Analgesic effect only, no benefit for healing
Bone: fracture Contra-indicated Probable harmful effects on bone formation
Bone: stress fracture Contra-indicated Probable harmful effects on bone formation
Muscle: acute muscle tear Probably not useful and
perhaps not indicated
Inhibits protein synthesis and
inflammatory reaction
Muscle: contusion Potentially useful In case of deep contusion or history of
ossifying myositis
Muscle: DOMS Potentially useful Sufficient tissue concentration (requires taking
NSAIDs several days before the eccentric exercise
NSAIDs: non-steroidal anti-inflammatory drugs; DOMS: Delayed Onset Muscle Soreness.
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injuries, who also benefited from physical therapy. The
evolution of pain (primary effectiveness criterion) or swelling
(measure of thigh circumference) or muscle strength (iso-
kinetic evaluation) was not different in the three groups in this
study until 7 days after the injury [39].
Finally, the use of NSAIDs is probably less debatable in
cases of deep muscle contusions, a frequent source of Myositis
ossificans. However, no prospective random controlled study
has clearly documented the effectiveness of NSAIDs in
preventing the appearance of heterotopic ossification. None-
theless, a recent analysis in the literature [27] recommends
taking indomethacin or other NSAIDs for at least 7 days after
an ‘‘at-risk’’ deep muscle contusion. This recommendation is
based only on works documenting the positive effect of
NSAIDs in preventing heterotopic ossification after prosthetic
replacement, without mentioning an effect size calculated on
the basis of all the referenced studies.
In summary, our review of the literature doesn’t allow us
to draw conclusions about the formal interest of taking
NSAIDs for acute muscle injuries, except perhaps to prevent
apparition of DOMS after eccentric exercise or to prevent
heterotopic ossification after deep muscles contusions. On
the contrary, such action could be counter-productive,
inhibiting prostaglandin formation as well as protein
synthesis.
1.5. Conclusion
In sports medicine, especially for acute or chronic injuries of
the musculoskeletal system, high-quality studies on the use of
NSAIDs are still rare. Yet, using NSAIDs or analgesics to treat
many sports injuries is a common practice among athletes. The
systematic prescription of NSAIDs is certainly still too
frequent. Their administration should respond to precisecriteria. It seems obvious that sports medicine specialists
should think about the fundamental problems involved.
In addition, NSAIDs are far from being without harmful
consequences for musculoskeletal tissue repair and organic
systems (e.g., digestive tract, kidneys). Can we justify masking
the painful symptoms of athletes to allow them the shortest
possible time away from their sport, perhaps at the detriment of
their tissue healing in the medium term and their functional
recuperation in the long term.
A reasonable use of these substances seems to be necessary.
However, although the prescription of NSAIDs is justified in
certain cases, it should always be the minimal effective dose
and the shortest possible length of administration. Table 2
presents a summary of our conclusions based on our non-
exhaustive review of the literature.
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Les mesures imme´diates prises en urgences lors d’un
traumatisme sportif sont connues de tous : glace, repos,
e´le´vation, compression (protocole GRE´C). Meˆme s’il apparaıˆt
de bon aloi de continuer a` pre´coniser leur emploi, aucune e´tude
n’a ve´ritablement de´montre´ a` ce jour l’inte´reˆt de leur
application [15].
Afin de juguler l’e´pisode douloureux traumatique ou post-
traumatique, il est de pratique courante de prescrire des anti-
inflammatoires non ste´roı¨diens (AINS) ou des antalgiques. Les
Tableau 1
Classification des AINS par demi-vie.
Demi-vie courte < 6 h Demi-vie longue > 6 h
Aspirine 25–330 Diflunisal 8–12
Diclofe´nac 1–2 Naproxe`ne 12–15
Ibuprofe`ne 1–2.5 Salsalate 3,5–16
Ke´toprofe`ne 1.5–4 Sulindac 16–18
Fe´noprofe`ne 2–3 Piroxicam 24–38
Acide me´fe´namique 2–4 Nabume´tone 24
Me´clofe´namate 3–4 Oxaprozine 25




Fig. 1. Cascade de l’acide arachidonique.
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secondaires et, malgre´ tout, pour certains, en vente libre ou au
moins accessibles sans controˆle me´dical strict.
Les athle`tes consomment re´gulie`rement ces substances pour
diverses raisons : afin de poursuivre leur activite´ sportive
malgre´ une le´sion traumatique aigue¨ ou de surcharge, pour
haˆter un retour sur le terrain de sport apre`s une le´sion, voire en
guise de prophylaxie. Les AINS ont ainsi e´te´ les me´dicaments
les plus utilise´s chez les sportifs canadiens aux Jeux
Olympiques de Sydney [20]. De meˆme, une enqueˆte effectue´e
aupre`s de joueurs de football ame´ricain a montre´ que un athle`te
sur sept de niveau « high school » consomme quotidiennement
des AINS et que 29 % d’athle`tes de niveau « colle`ge » en
prennent pre´ventivement le jour d’une compe´tition [52].
Warner et al. retrouvent une incidence similaire : inde´pendam-
ment d’effets antalgiques, les athle`tes e´voquent un possible
gain de performance pour justifier la prise de ces substances
[54].
Pour un nombre non ne´gligeable de praticiens, les
connaissances me´dicales sur les conse´quences nocives de
l’utilisation chronique d’AINS se limitent a` la proble´matique
gastro-intestinale, ainsi qu’a` celle de la fonction re´nale. Or, la
litte´rature me´dicale re´cente montre que les effets de´le´te`res des
AINS s’e´tendent e´galement au me´tabolisme et a` la croissance
des principaux tissus constituants l’appareil musculosquelet-
tique [44]. Il se pose donc un proble`me clinique « e´thique » :
faut-il ne tenir compte que de l’effet antalgique a` court terme
des AINS afin de privile´gier la performance imme´diate ou alors
mettre l’accent sur les conse´quences potentiellement de´le´te`res
a` long terme de leur utilisation ?
Cette revue qui ne se veut pas une analyse syste´matique au
sens strict du terme de l’ensemble de la litte´rature sur le sujet,
mais plutoˆt une mise au point, a pour but d’aider le praticien de
premier recours, le me´decin ge´ne´raliste et le me´decin du sport a`
e´valuer les risques et be´ne´fices inhe´rents a` l’utilisation
occasionnelle ou re´gulie`re des AINS chez l’athle`te, qu’il
s’agisse de le´sions ligamentaires, tendineuses, osseuses ou
musculaires.
Pour la re´aliser, nous avons utilise´ les sources de donne´es
classiques Pubmed et Embase entre 1997 et 2008, avec les
mots cle´s suivants : AINS, appareil locomoteur, tendino-
pathies, fractures osseuses, le´sions ligamentaires et de´chi-
rures musculaires. Nous avons ensuite se´lectionne´, en lisant
individuellement chaque titre et abstract de tous les articles,
ceux qui traitaient du roˆle des AINS dans des pathologies de
l’appareil moteur fre´quemment rencontre´es en me´decine du
sport. Nous avons garde´ 55 articles au total, soit revues de
litte´rature, me´ta-analyses ou e´tudes randomise´es controˆle´es
parues dans des journaux a` politique e´ditoriale. Aucun essai
n’a e´te´ fait de classifier ces e´tudes en termes de qualite´
me´thodologique.
2.2. Anti-inflammatoires non ste´roı¨diens : ge´ne´ralite´s
2.2.1. Modes d’action
La prise orale, voie d’administration la plus fre´quente
des AINS implique un passage digestif, sanguin, puis unme´tabolisme he´patique ou re´nal, selon leurs proprie´te´s
individuelles. Les AINS peuvent e´galement eˆtre de´livre´s sous
forme topique ou par injection intramusculaire.
Un exemple de classification des AINS [13], en particulier
selon leur demi-vie, de la nature des processus inflammatoires
et de leurs effets cellulaires est pre´sente´ de fac¸on synthe´tique
dans le Tableau 1.
Le me´canisme d’action principal des AINS est une
inhibition de la synthe`se des prostaglandines (Fig. 1) a` partir
de l’acide arachidonique, par un blocage de la cyclo-oxyge´nase
(Cox), tandis qu’une partie de la cascade de l’acide
arachidonique peut se poursuivre par la voie de la lipo-
oxyge´nase. Un effet d’inhibition de la migration, de l’agre´ga-
tion et sur la fonction des neutrophiles, puis des macrophages
est e´galement connu. Deux iso-enzymes (comportant proba-
blement des sous-classes) de la Cox sont identifie´s, respective-
ment une forme constitutive appele´e Cox-1 et une forme
inductible Cox-2. La Cox-2 est surexprime´e localement lors
d’e´tats inflammatoires et la synthe`se des prostaglandines qui en
re´sulte entretient le processus le´sionnel. Les AINS traditionnels
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re´ponse inflammatoire, mais e´galement la protection gastrique
et interfe`re avec la fonction re´nale. Les inhibiteurs se´lectifs de
la Cox-2 ont e´te´ introduits afin d’obtenir, par le biais de leur
se´lectivite´, une re´duction de ces effets secondaires, en
particulier gastriques.
A` la lumie`re de ce qui pre´ce`de, il paraıˆt de plus en plus
e´vident que les AINS, de par leur inhibition de la re´ponse
inflammatoire pre´coce, peuvent, en alte´rant la cicatrisation
naturelle d’une le´sion, avoir un impact ne´gatif sur le processus
de re´paration.
2.2.2. Effets inde´sirables
La liste des effets inde´sirables des AINS, tous types
confondus, concerne essentiellement le syste`me gastro-
intestinal, cardiovasculaire, he´patique et re´nal.
La toxicite´ gastro-intestinale (dyspepsie, nause´es, ulce`res et
saignements) apparaıˆt surtout lors d’une prise chronique. Mais
de`s un mois de prise re´gulie`re d’un AINS, en termes de
survenue d’he´morragie du tractus gastro-intestinal supe´rieur, il
apparaıˆt un risque relatif (RR) nettement accru par rapport aux
sujets te´moins, respectivement de 4,0 pour des AINS
classiques (diclofe´nac, naproxe`ne), de 3,0 pour le diclofe´nac
associe´ a` dumisoprostol, de 1,9 pour le rofe´coxib et de 1,0 pour
le ce´le´coxib [23,27]. A` titre pre´ventif, il est donc recommande´
de limiter la dure´e d’administration, de faire coı¨ncider la prise
me´dicamenteuse avec les repas et/ou de prescrire un inhibiteur
de la pompe a` proton, voire une association diclofe´nac–
misoprostol.
C’est donc dans le but de re´duire les effets ne´fastes digestifs
que les inhibiteurs Cox-2 se´lectifs ont e´te´ introduits de`s 1999.
Les e´tudes publie´es par la suite ont toutefois mis en e´vidence
que ces substances engendraient une perturbation de la balance
prostacyclines–thromboxane. Or cet e´quilibre est primordial
dans le maintien de l’home´ostasie vasculaire [41], au risque de
voir le risque thrombotique augmenter [17]. Le rofe´coxib a e´te´
retire´ du marche´ en raison de l’augmentation de l’effet pro-
thrombotique responsable d’un nombre accru d’accidents
vasculaires. Sur le marche´ suisse, le valde´coxib a e´te´ e´galement
e´te´ retire´, par se´curite´. Seul le ce´le´coxib, a e´te´ maintenu. Si l’on
e´value le RR de survenue d’un infarctus du myocarde, on rele`ve
que celui du rofe´coxib s’e´le`ve a` 1,35 avec un effet dose
de´pendant (au-dela` de 25 mg/j, il e´quivaut a` 2,19), alors qu’il
est limite´ a` 1,06 pour le ce´le´coxib. De meˆme, des valeurs
e´leve´es de RR sont retrouve´es parmi certains AINS non
se´lectifs, tels que le diclofe´nac et l’indome´tacine, respective-
ment 1,40 et 1,30 [26].
Le risque de complications he´morragiques post-
traumatiques existe par ailleurs chez tous les sportifs engage´s
dans des sports de contact ou « a` risque » [33,44].
Un effet secondaire moins fre´quent est l’atteinte re´nale,
plutoˆt observe´e chez le sujet aˆge´, mais aussi chez le sujet
de´shydrate´, situation fre´quente lors de la pratique sportive.
Quel que soit le type d’anti-inflammatoire choisi, le risque
de survenue d’effets inde´sirables est donc re´el. Il existe
toutefois une corre´lation entre la dure´e du traitement et
l’apparition de ces complications.2.3. Anti-inflammatoires non ste´roı¨diens : formes
parente´rales
2.3.1. Applications topiques
La rarete´ des d’e´tudes cliniques a` large e´chelle concernant
les substances anti-inflammatoires topiques rendent les
conclusions certes limite´es, mais inte´ressantes.
Ainsi, pour ce qui concerne la pe´ne´tration tissulaire, des
doses the´rapeutiques en sous-cutane´ semblent eˆtre obtenues,
tout en re´duisant les effets inde´sirables syste´miques par un taux
circulant plus bas [42]. Une me´ta-analyse a porte´ sur
l’utilisation du diclofe´nac et du ke´toprofe`ne en application
topique par rapport au placebo, dans le contexte de le´sions
sportives be´nignes aigue¨s ou chroniques des parties molles,
incluant plus de 10 000 patients. Les crite`res d’efficacite´ e´taient
une re´duction d’au moins 50 % de la douleur, ainsi que
l’e´valuation de la tole´rance au traitement. Elle a re´ve´le´ une
efficacite´ the´rapeutique des AINS supe´rieure au placebo avec,
en conditions aigue¨s (dure´e maximale d’une semaine), un
be´ne´fice relatif de 1,7 et un nombre de sujets a` traiter (NNT) de
3,9. En conditions chroniques (dure´e de plus de
deux semaines), le be´ne´fice relatif est de 2,0 et le NNT de
3,1 [30].
L’apparition d’AINS sous forme de patch, plus re´cente,
permet une libe´ration prolonge´e et controˆle´e de la substance
active sur 12 a` 24 heures. Plusieurs e´tudes controˆle´es re´centes
utilisant des patches de diclofe´nac [9] et de ke´toprofe`ne [25]
(versus gel et/ou placebo) ont confirme´ l’efficacite´ des patches.
Les crite`res d’efficacite´ syste´matiquement retenus e´taient a`
nouveau l’e´valuation de la douleur et de la tole´rance au
traitement. Leur utilisation ne permet toutefois pas un retour
acce´le´re´ au sport [4,34].
2.3.2. Formes injectables intramusculaires
La seule e´tude publie´e, dont la qualite´ est discutable,
concerne le ke´torolac [7] et conclut a` l’absence de re´duction de
la douleur par rapport a` l’administration orale. Les effets
inde´sirables, tels que le risque he´morragique global [29] et les
complications re´nales [10] semblent, en revanche, plus
marque´s.
Cette forme d’administration reste malgre´ tout tre`s prise´e
dans les milieux sportifs professionnels (« smart bomb ») dans
le contexte d’e´ve`nements particuliers [48].
2.4. Anti-inflammatoires non ste´roı¨diens et appareil
musculosquelettique
2.4.1. Le´sions ligamentaires
Le processus de re´paration d’une le´sion ligamentaire aigue¨
s’effectue en trois phases : une re´ponse inflammatoire initiale
avec de´tersion des tissus le´se´s, une phase de prolife´ration
comprenant la formation de ne´o-collage`ne et enfin une pe´riode
de remodelage qui peut durer plusieurs mois. Les e´tudes
disponibles concernent l’utilisation du piroxicam, de l’ibupro-
fe`ne et des inhibiteurs Cox-2 dans la le´sion du ligament
collate´ral me´dial du genou sur le mode`le animal [40]. Les
re´sultats sont contradictoires :
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 a` moyen terme, la re´sistance tensionnelle du ligament est
majore´e, re´duite ou inchange´e ;
 a` plus longue e´che´ance, des effets potentiellement de´le´te`res
sur la cicatrisation sont de´crits [6,8,31].
In vitro, la synthe`se prote´inique dans des fibroblastes
humains est inhibe´e par l’adjonction d’indome´tacine [2].
Chez l’homme, les entorses aigue¨s de cheville ou de
genou sont les plus e´tudie´es. Dans une e´tude comparant
l’utilisation d’un placebo a` un traitement par ibuprofe`ne, les
auteurs concluent a` une douleur et une tume´faction
pre´cocement diminue´e ; les amplitudes articulaires sont
ame´liore´es et la mise en charge est plus rapide [13]. Ces
effets positifs sont en re`gle ge´ne´rale observables jusqu’au
septie`me jour. Apre`s six mois, en revanche, le groupe traite´
par un AINS (piroxicam 20 mg/j pendant sept jours)
de´montre une amplitude articulaire re´duite, une laxite´
ante´rieure augmente´e et un taux de re´cidive accru (25 %)
[43].
Les AINS paraissent donc avoir un impact positif sur
l’e´volution initiale lors d’une ligamentaire aigue¨, raison pour
laquelle des AINS pendant trois a` sept jours peuvent eˆtre
administre´s [27]. Cela pourrait permettre une reprise plus
pre´coce de l’activite´ sportive. A` long terme, ce retour anticipe´
est toutefois susceptible de se faire au de´triment d’une
cicatrisation de bonne qualite´.
2.4.2. Le´sions tendineuses
Le roˆle des AINS dans le traitement des tendinopathies de
surcharge est incertain et de´battu. De fait, les tendinopathies
chroniques ne pre´sentent pas de re´action inflammatoire [16],
hormis dans certains cas de bursite ou de synovite associe´e.
En revanche, il existe fre´quemment une ne´ovascularisation et
une ne´o-innervation persistante dont la pre´sence, pathologi-
que, pourrait eˆtre en partie responsable de la douleur [1]. Une
me´ta-analyse qui a identifie´ 37 e´tudes cliniques randomise´es,
dont 17 placebo-controˆle´es, met en e´vidence que seule la
douleur a` bre`ve e´che´ance (sept a` dix jours) est re´duite,
particulie`rement au niveau de l’e´paule. L’efficacite´ antalgi-
que est nettement moindre pour le coude, le tendon rotulien
et achille´en. A` long terme, il n’existe pas d’e´vidence que les
AINS soient effectifs, alors que le risque d’effets inde´sirables
augmente. Cette e´tude ne mentionne pas d’effet taille calcule´
sur la base des diverses e´tudes recense´es [3]. La gue´rison
d’une tendinopathie ne semble, en outre, pas eˆtre modifie´e
par la prise d’un AINS [24]. Au contraire, l’effet antalgique
des AINS permettrait au sportif d’augmenter pre´cocement les
contraintes sur son tendon et donc de compromettre la
gue´rison [22].
Dans les atteintes aigue¨s, seule la tendino-bursite de l’e´paule
et la te´nosynovite de De Quervain paraissent des indications
potentielles pour un traitement de courte dure´e (jusqu’a`
14 jours) par ce´le´coxib [19] ou naproxe`ne [36] versus placebo,
avec comme crite`res d’efficacite´ essentiels la re´duction de
l’intensite´ maximale de la douleur au repos et la tole´rance au
traitement.2.4.3. Le´sions osseuses
Les PGE jouent un roˆle important en home´ostasie osseuse.
Elles stimulent la re´sorption osseuse en augmentant le nombre
et l’activite´ des oste´oclastes et stimulent la formation osseuse
en augmentant la re´plication et la diffe´rentiation des
oste´oblastes [53]. On comprend de`s lors que toute substance
qui alte`re la synthe`se des PG puisse avoir un impact sur l’os.
Les effets inhibiteurs des AINS sur la formation osseuse sont
d’ailleurs utilise´s dans la pre´vention des ossifications he´te´ro-
topiques apre`s chirurgie prothe´tique [11].
Les e´tudes animales de´montrent un retard de consolidation
osseuse lors de l’administration d’AINS, y compris pour les
Cox-2 se´lectifs [55].
En traumatologie aigue¨ et en phase postope´ratoire, les
e´tudes humaines montrent des re´sultats non univoques. Le plus
souvent, ces e´tudes sont re´trospectives ou refle`tent des
situations particulie`res telles les fusions rachidiennes. Les
effets de´le´te`res des AINS varient selon les substances choisies
ainsi que selon la dure´e de prise me´dicamenteuse. Un retard de
consolidation osseuse a notamment e´te´ de´crit a` de nombreuses
reprises [12,18,37]. En raison de ces effets sur la formation
osseuse, il convient de les e´viter, dans tous les cas au minimum
durant la premie`re semaine apre`s une fracture. Par la suite,
meˆme en l’absence d’effets ne´fastes certains, leur emploi ne se
justifie plus ve´ritablement, les antalgiques devant eˆtre
suffisants. Lors de fracture lente ou fracture de stress, et pour
les meˆmes raisons, les AINS ne devraient pas eˆtre utilise´s.
Il convient donc d’e´viter l’administration de ces substances,
particulie`rement durant la premie`re semaine apre`s une fracture
ainsi que lors d’une fracture de stress.
2.4.4. Le´sions musculaires
La gravite´ d’une le´sion musculaire de´pend du degre´
d’atteinte de ses deux constituants principaux, que sont la
composante contractile et le tissu de soutien. Dans les suites
imme´diates d’une rupture de fibres musculaires, une ne´crose
des myofibres survient, associe´e a` une re´action inflammatoire
[14] et domine´e par la pre´sence de neutrophiles et de
macrophages. Leur roˆle exact, favorable ou de´le´te`re, n’est
pas encore connu [5,28,38,45–47]. Pour certains auteurs, les
neutrophiles seraient responsables de la libe´ration de cytokines
et de radicaux libres, qui pourraient aggraver la le´sion initiale.
Dans un futur proche, des inhibiteurs se´lectifs de la production
de radicaux libres pourraient ainsi voir le jour, ce qui
constituerait un traitement pharmacologique innovateur [49].
La phase de re´paration qui suit permet la phagocytose du
mate´riel ne´crotique par les macrophages, e´galement source de
cytokines et de facteurs de croissance, et la production d’un
tissu fibreux. Un processus de remodelage est alors mis en place
pour permettre la re´ge´ne´ration de nouvelles fibres musculaires
et l’organisation de la cicatrice fibreuse [50].
Il existe de nombreux mode`les animaux de le´sions
musculaires traite´es par des AINS. La transposition de ces
re´sultats a` l’eˆtre humain e´tant hasardeuse et du fait de la
variabilite´ me´thodologique de ces e´tudes, il est difficile de tirer
des conclusions univoques. De ce fait, nous ne rapportons que
les re´sultats d’e´tudes effectue´es sur l’homme.
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un antalgique (ace´taminophe`ne 4 g/j) et a` un placebo, lors de
courbatures musculaires a` de´but retarde´ (DOMS) ne modifie
pas la concentration musculaire des neutrophiles ou des
macrophages dans les trois groupes [35]. De meˆme, pour ce
qui concerne les crite`res d’efficacite´ secondaires que sont le
taux de cre´atine kinase (CK) ou de PGE2 et l’intensite´ des
douleurs, il n’existe aucune diffe´rence entre les groupes. Une
inhibition e´quivalente au niveau de la production des
prostaglandines et de la synthe`se prote´ique est constate´e,
que ce soit lors de la prise d’un AINS ou d’un antalgique
[51,52].
En revanche, lorsque l’administration d’un AINS (indome´-
tacine 100 mg/j de j  4 a` j + 8) est re´alise´e avant la survenue
de la le´sion, on constate une re´duction des cellules satellites
induite par l’effort [21] qui sont indispensables a` la
re´ge´ne´ration et tributaires de la pre´sence de PG. Ainsi, la
prise re´gulie`re d’AINS, pratique courante dans certains milieux
sportifs, permet peut-eˆtre d’atteindre des concentrations
tissulaires suffisantes pour possiblement modifier la re´ponse
locale.
Cette hypothe`se est e´galement e´taye´e dans un travail qui
rapporte que l’administration prolonge´e de diclofe´nac
commence´e 15 jours avant un effort excentrique inhabituel,
par rapport a` un placebo, permet de limiter l’augmentation des
CK et de diminuer la dure´e d’inconfort lie´ aux courbatures,
deux crite`res d’efficacite´ commune´ment e´tudie´s dans le
domaine musculaire [32].
Dans le contexte plus classique d’atteinte musculaire
traumatique aigue¨ (type de´chirure ou « claquage »), la prise
d’AINS (diclofe´nac : 150 mg/j), d’antalgiques (me´clofe´namate :
300 mg/j) ou d’un placebo ne modifie pas le devenir des sujets
victimes de le´sions musculaires des ischio-jambiers be´ne´ficiant
aussi d’un traitement de physiothe´rapie. L’e´volution, qu’il
s’agisse de la douleur (crite`re d’efficacite´ principal), de la
tume´faction de la cuisse (circonfe´rence) ou de la force
musculaire (e´valuation isocine´tique), n’est pas diffe´renteTableau 2
Conclusions des auteurs concernant l’utilisation des AINS en me´decine du sport.
Type de le´sion Impact des AINS
Ligament : Entorse aigue¨ Possiblement et potentiellement
utiles a` court terme
Tendon : Te´nosynovite aigue¨ Possiblement et potentiellement ut
Tendon : Tendinopathie de surcharge Probablement inutiles
Os : Fracture Non indique´s
Os : Fracture lente Non indique´s
Muscle : De´chirure aigue¨ Probablement inutiles, voire non i
Muscle : Contusion Potentiellement utiles
Muscle : DOMS Potentiellement utiles
AINS : anti-inflammatoires non ste´roı¨diens ; DOMS: delayed onset muscle sorenedans les trois groupes conside´re´s jusqu’a` sept jours post-le´sion
[39].
Enfin, l’utilisation des AINS est probablement moins
discutable en cas de contusion musculaire profonde, source
fre´quente de myosite ossifiante. Ne´anmoins, dans cette
situation, aucune e´tude prospective controˆle´e randomise´e ne
documente clairement l’efficience des AINS en termes de
pre´vention de l’apparition d’ossifications he´te´rotopiques. Une
analyse re´cente de la litte´rature [27] recommande pourtant la
prise d’indome´tacine ou d’autres AINS pendant au moins sept
jours apre`s une contusion musculaire profonde « a` risque ».
Cette proposition n’est faite que sur la base des travaux
documentant l’effet positif des AINS dans la pre´vention de
survenue des ossifications he´te´rotopiques apre`s remplacement
prothe´tique, sans pourtant mentionner un effet taille calcule´ sur
la base de toutes les e´tudes re´fe´rence´es.
En re´sume´, notre revue ne permet pas de conclure a` l’inte´reˆt
formel de la prise d’anti-inflammatoires lors de le´sions
musculaires aigue¨s, sauf peut-eˆtre en pre´vention des courba-
tures musculaires retarde´es post-excentrique ou d’ossifications
he´te´rotopiques post-contusion. Au contraire, une telle prise
pourrait s’ave´rer contre-productive, inhibant la formation des
PG, ainsi que la synthe`se prote´ique.
2.5. Conclusions
En me´decine du sport, et plus pre´cise´ment lors de le´sions
aigue¨s ou chroniques de l’appareil musculosquelettique, les
e´tudes de haute qualite´ sur l’utilisation des AINS sont encore
rares. L’emploi d’AINS ou d’antalgiques dans la prise en
charge d’un grand nombre de le´sions sportives reste pourtant
une pratique courante. Leur prescription syste´matique est
meˆme certainement encore trop fre´quente et leur administration
devrait re´pondre a` des crite`res pre´cis. Il paraıˆt e´vident qu’une
re´flexion s’impose.
En outre, les AINS sont loin d’eˆtre de´nue´s d’effets de´le´te`res
sur la re´paration tissulaire musculosquelettique, ainsi queCommentaires
Re´duction douleur et tume´faction
Retour au sport acce´le´re´
Laxite´ re´siduelle a` long terme (???)
Dure´e courte recommande´e (< 5 j)
iles Re´duction inflammation aigue¨ ; aide a` la re´cupe´ration
Antalgie seulement, aucun be´ne´fice sur la gue´rison
Effets probablement de´le´te`res sur la formation osseuse
Effets probablement de´le´te`res sur la formation osseuse
ndique´s Inhibent synthe`se prote´ique et la re´action inflammatoire
Si contusion profonde ou ante´ce´dente de myosite ossifiante
Concentration tissulaire suffisante (plusieurs jours de
prise avant l’effort excentrique)
ss.
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rein). Est-il donc justifie´ de masquer les symptoˆmes douloureux
d’un athle`te pour lui permettre une interruption la plus courte
possible de la pratique sportive, au de´triment peut-eˆtre de la
gue´rison a` moyen terme et, par conse´quent, de la re´cupe´ration a`
plus long terme ?
Ainsi, une utilisation raisonne´e de ces substances est
ne´cessaire et le Tableau 2 en repre´sente une synthe`se, base´e sur
cette revue non totalement exhaustive de la litte´rature.
Finalement, si leur prescription est dans certains cas
justifie´e, il devrait toujours s’agir de la dose minimale efficace
et de la dure´e ne´cessaire la plus courte possible.
Conflit d’inte´reˆt
Aucun conflit d’inte´reˆt n’est a` signaler entre les auteurs et les
firmes pharmaceutiques de´veloppant et produisant antalgiques
et AINS.
References
[1] Alfredson H. Chronic tendon pain: implications for treatment, an update.
Curr Drug Target 2004;5:407–10.
[2] Almekinders LC, Baynes AJ, Bracey LW. An in-vitro investigation into
the effects of repetitive motion and NSAIDs on human fibroblasts. Am J
Sports Med 1995;23:119–23.
[3] Andres BM, Murrell GA. Treatment of tendinopathy: what works, what
does not, and what is on the horizon. Clin Orthop Relat Res
2008;466(7):1539–54.
[4] Bolin DJ. Transdermal approaches to pain in sports injury management.
Curr Sports Med Rep 2003;2:303–9.
[5] Bondensen BA, Mills ST, Kegley KM, et al. The Cox-2 pathway is
essential during early stages of skeletal muscle regeneration. Am J Physiol
Cell Physiol 2004;287:475–83.
[6] Dahners LE, Gilbert JA, Lester GE, et al. The effect of a non-steroidal anti-
inflammatory drug on the healing of ligaments. Am J Sports Med
1988;16:641–6.
[7] Dietzel DP, Hedlund EC. Injections and return to play. Curr Pain Headache
Rep 2005;9:11–6.
[8] Elder CL, Dahners LE, Weinhold PD. A Cox-2 inhibitor impairs ligament
healing in the rat. Am J Sports Med 2001;29:801–5.
[9] Esparza F, Cobian C, Jimenez JF, et al. Topical ketoprofen patch versus
diclofenac gel: efficacy and tolerability in benign sport related soft tissue
injuries. Br J Sports Med 2007;41:134–9.
[10] Feldman HI, Kinman JL, Berlin JA, et al. Parenteral ketorolac: the risk for
acute renal failure. Ann Intern Med 1997;126:193–9.
[11] Fransen M, Neal B. Non-steroidal anti-inflammatory drugs for preventing
heterotopic bone formation after hip arthroplasty. Cochrane Database Syst
Rev 2004;3:CD001160.
[12] Gaston MS. Inhibition of fracture healing. J Bone Joint Surg Br 2007;89-
B:1553–60.
[13] Hertel J. The role of NSAIDs in the treatment of acute soft tissue injuries. J
Athl Train 1997;32:350–8.
[14] Ja¨rvinen TAH, Ja¨rvinen TL, Ka¨a¨ria¨nen M, et al. Muscle Injuries Biology
and Treatment. Am J Sports Med 2005;33:745–64.
[15] Ja¨rvinen TAH. Muscle injuries: optimising recovery. Best Pract Res Clin
Rheumatol 2007;21:317–31.
[16] Khan KM, Cook JL, Bonar F, et al. Histopathology of common tendino-
pathies: update and implications for clinical management. Sports Med
1999;27:393–408.
[17] Koenig W. Inflammation and coronary heart disease: an overview. Cardiol
Rev 2001;9:31–5.
[18] Koester MC, Spindler KP. Pharmacologic agents in fracture healing. Clin
Sports Med 2006;25:63–73.[19] Lane LB, Boretz RS, Stuchin SA. Treatment of De Quervain’s disease:
role of conservative management. J Hand Surg [Br] 2001;26:258–60.
[20] Lippi G, Franchini M, Guidi GC. Non steroidal anti-inflammatory drugs
(NSAIDs) in athletes. Br J Sports Med 2006;40:661–3.
[21] Mackey AL, Kjaer M, Dandanell S, et al. The influence of anti-inflam-
matory medication on exercise-induced myogenic precursor cell
responses in humans. J Appl Physiol 2007;103:425–31.
[22] Magra M, Maffulli N. NSAIDs in tendinopathy: friend or foe. Clin J Sport
Med 2006;16:1–3.
[23] Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper
gastro-intestinal hemmorrage in elderly patients given Cox-2 inhibitors or
conventional non-steroidal anti-inflammatory drugs. BMJ 2002;325:624.
[24] Marsolais D, Coˆte´ CH, Frenetta J. NSAIDs reduce neutrophil and macro-
phage accumulation but does not improve tendon regeneration. Lab Invest
2003;83:991–9.
[25] Mazieres B, Rouanet S, Guillon Y. Topical ketoprofen patch in the
treatment of tendonitis: randomized, double-blind, controlled study. J
Rheumatol 2005;32:1563–70.
[26] McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclo-
oxygenase. A systematic revue of the observation studies of selective and
non selective inhibitors of Cox-2. JAMA 2006;296(13):1633–44.
[27] Mehallo CJ, Drezner JA, Bytomski JR. Practical management: NSAIDs
use in athletic injuries. Clin J Sport Med 2006;16:170–4.
[28] Mendias CL, Tatsumi R, Allen RE. Role of cyclo-oxigenase-1 and -2 in
satellite cell proliferation, differentiation, and fusion. Muscle Nerve
2004;30:497–500.
[29] Milne JC, Russell JA, Woods GW, et al. Effect of toradol on ecchymosis
following ACL reconstruction. Am J Knee Surg 1995;1:24–7.
[30] Moore RA, Tramer MR, Carroll D. Quantitative systematic review of
topically applied NSAIDs. BMJ 1998;316:333–8.
[31] Moorman CT, Kukreti U, Fenton DC. The early effect of ibuprofen on the
mechanical properties of healing medial collateral ligament. Am J Sports
Med 1999;27:738–41.
[32] O’Graddy M, Hackney AC, Schneider K, et al. Diclofenac sodium
(Voltaren1) reduced exercise-induced injury in human skeletal muscle.
Med Sci Sports Exerc 2000;32:1191–6.
[33] Owens S, Baglin T. Recurrent haematomas of the thigh. Br J Sports Med
2000;34:122–3.
[34] Paoloni JA, Orchard JW. The use of therapeutic medications for soft tissue
injuries in sports medicine. MJA 2005;183:384–8.
[35] Peterson JM, Trappe TA, Mylona E, et al. Ibuprofen and acetaminophen:
effect on muscle inflammation after eccentric exercise. Med Sci Sports
Exerc 2003;35:892–6.
[36] Petri M, Hufman SL, Waser G, et al. Celecoxib effectively treats patients
with acute shoulder tendonitis/bursitis. J Rheumatol 2004;31:1614–20.
[37] Pountos I, Georgouli T, Blokhuis TJ, et al. Pharmacological agents and
impairment of fracture healing: what is the evidence? Injury 2008;39:384–
94.
[38] Rahusen FTG, Weinhold PS, Almekinders LC. Nonsteroidal anti-inflam-
matory drugs and acetaminophen in the treatment of an acute muscle
injury. Am J Sports Med 2004;32:1856–9.
[39] Reynolds JF, Noakes TD, Schwelinus MP, et al. Non-steroidal anti-
inflammatory drugs fail to enhance healing of acute hamstring injuries
treated with physiotherapy. S Afr Med J 1995;85:517–22.
[40] Rochcongar P. Les diffe´rents modes de cicatrisation pe´riphe´rique. In:
Rodineau J, Saillant G, editors. La le´sion ligamentaire pe´riphe´rique
re´cente. Ed. Masson; 2003. p. 30–7.
[41] Schmedtje JF, Ji YS, Liu WL, Dubois RN, Runge MS. Hypoxia induces
Cox-2 via the NF-kappa B p65 transcription factor in human vascular
endothelial cells. J Biol Chem 1997;272:601–8.
[42] Singh P, Roberts MS. Skin permeability and local tissue concentrations of
NSAIDs after topical application. J Pharmacol Exp Ther 1994;268:144–
51.
[43] Slatyer MA, Hensley MJ, Lopert R. A randomized controlled trial of
piroxicam in the management of acute ankle sprain in Australian army
recruits. Am J Sports Med 1997;25:544–53.
[44] Smith BJ, Collina SJ. Pain medications in the locker room: to dispense or
not. Curr Sports Med Rep 2007;6:367–70.
J.-L. Ziltener et al. / Annals of Physical and Rehabilitation Medicine 53 (2010) 278–288288[45] Soltow QA, Betters JL, Sellman JE, et al. Ibuprofen inhibits skeletal
muscle hypertrophy in rats. Med Sci Sports Exerc 2006;38:840–6.
[46] Thorsson O, Rantanen J, Hurme T, et al. Effects of non-steroidal anti-
inflammatory medication on satellite cell proliferation during muscle
regeneration. Am J Sports Med 1998;26:172–6.
[47] Tidball JG. Inflammatory process in muscle injury and repair. Am J
Physiol Regul Integr Comp Physiol 2005;288:R345–53.
[48] Tokish JM, Powell ET, Schlagel TF, et al. Ketorolac use in the NFL. Phys
Sports Med 2002;9:19–24.
[49] Toumi H, Best TM. The inflammatory response: friend or enemy for
muscle injury. Br J Sports Med 2003;37:284–6.
[50] Trappe TA, White F, Lambert CP, et al. Effect of ibuprofen and acetamin-
ophen on postexercise muscle protein synthesis. Am J Physiol Endocrinol
Metab 2001;282:E551–6.[51] Trappe TA, Fluckey JD,White F, et al. Skeletal muscle PGF2a and PGF2 in
response to eccentric resistance exercise: Influence of ibuprofen and
acetaminophen. J Clin Endocrin Met 2001;86:5067–70.
[52] Tricker R. Painkilling drugs in collegiate athletics. J Drug Educ 2000;
30:313–24.
[53] Vuolteenaho IK, Moilanen T, Moilanen E. Non-steroidal anti-inflamma-
tory drugs, cyclooxygenase-2 and the bone healing process. Basic Clin
Pharmacol Tox 2007;102:10–4.
[54] Warner DC, Schnepf G, Barret MS, et al. Prevalence, attitudes, and
behaviors related to the use of nonsteroidal anti-inflammatory drugs
(NSAIDs) in student athletes. J Adolesc Health 2002;30:150–3.
[55] Wheeler P, Batt ME. Do non-steroidal anti-inflammatory drugs adversely
affect stress fracture healing? A short review. Br J Sports Med 2005;
39:65–9.
